Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.96 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.96 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.96 |
| ▸ | TSPO | P30536 | 1/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.96 |
| ▸ | HRH1 | P35367 | 1/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.96 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.96 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiotropium SCHEMBL7607795 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL440873 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL8625 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL15005742 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL14672487 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL19581677 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL4589 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL29527286 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL1405692 | 0.98 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL2231775 | 0.98 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304197-A1 | FORMULATIONS CONTAINING TIOTROPIUM, AMINO ACID AND ACID AND METHODS THEREOF | PULMATRIX OPERATING COMPANY, INC. (US) | 2017-10-26 | — | — | US | claimed |
| US-20170304198-A1 | IMPROVED STABILITY OF DRY POWDERS CONTAINING TIOTROPIUM AND AMINO ACID | PULMATRIX OPERATING COMPANY, INC. | 2017-10-26 | — | — | US | claimed |
| EP-3203985-A1 | IMPROVED STABILITY OF DRY POWDERS CONTAINING TIOTROPIUM AND AMINO ACID | Pulmatrix Operating Company, Inc. (US) | 2017-08-16 | — | — | EP | claimed |
| EP-3203982-A1 | FORMULATIONS CONTAINING TIOTROPIUM, AMINO ACID AND ACID AND METHODS THEREOF | Pulmatrix Operating Company, Inc. (US) | 2017-08-16 | — | — | EP | claimed |
| WO-2016057644-A1 | IMPROVED STABILITY OF DRY POWDERS CONTAINING TIOTROPIUM AND AMINO ACID | PULMATRIX OPERATING COMPANY, INC. (US) | 2016-04-14 | — | — | WO | claimed |
| WO-2016057641-A1 | FORMULATIONS CONTAINING TIOTROPIUM, AMINO ACID AND ACID AND METHODS THEREOF | PULMATRIX OPERATING COMPANY, INC. (US) | 2016-04-14 | — | — | WO | claimed |
| EP-2067779-B9 | Tiotropium salts, method for their production and medicinal formulas containing them | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | claimed |
| EP-2067779-B1 | Tiotropium salts, method for their production and medicinal formulas containing them | BOEHRINGER INGELHEIM INT (DE) | 2013-04-24 | — | — | EP | claimed |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-17 | — | — | US | claimed |
| US-20050131007-A1 | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | claimed |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
| CN-117280030-A | Agents, compositions and methods for treating hypoxia and ischemia related conditions | 梅兰德制药公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-107249570-B | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-08-09 | — | — | CN | disclosed |
| WO-2014007768-A1 | DRY POWDER INHALER COMPOSITIONS COMPRISING LONG ACTING MUSCORINIC ANTAGONISTS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2014-01-09 | — | — | WO | disclosed |
| US-20130302260-A1 | NOVEL PROPELLANT CONTAINING PREPARATIONS FOR TIOTROPIUM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| CN-101123970-A | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for the treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC (US) | 2008-02-13 | — | — | CN | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20050131007-A1 | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | CHRM3 3/4885CHRM2 1/4885CHRM1 12/4885 |
| US-20050131007-A1 | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | CHRM3, ADRB3, CHRNA5 | CHRM3 1/4885CHRM2 26/4885CHRM1 32/4885 |
| US-20130302260-A1 | NOVEL PROPELLANT CONTAINING PREPARATIONS FOR TIOTROPIUM | PDE6A, PDE6H, PDE6C | CHRM3 25/4885CHRM2 107/4885CHRM1 136/4885 |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | ADRB3, ADRB1, HSD3B1 | CHRM3 8/4885CHRM2 44/4885CHRM1 62/4885 |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | ADRB3, ADRB1, CHRM3 | CHRM3 3/4885CHRM2 32/4885CHRM1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.